Replies to post #1788 on Conatus Pharmaceuticals Inc. (CNAT)

[Lunacy_John Galt]

I do believe the data will be positive, but I've seen this type of activity before result in terrible data. Look at NVAX for example, late 2016 they expanded and fully built up operations for commercialization leading into their Ph3 top-line readout. Every indicator based on their behavior/activity screamed positive results. They were devastated when the placebo group performed better than the control group, and this was after strong Ph2 data. Management held a call to discuss the data, and couldn't barely speak they were so shocked. I'm long since $1.96 and holding strong, but I urge some caution with these data readouts.

[lorema]

All patients have done 3 biopsies. One at the beginning of the trial, the second alone year after and the third two year after the start of trial. I think they have a pretty clear idea of the drugs effect.